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Antibodies targeting T-cell inhibitory pathways, such as CTLA-4 and PD-1/PD-L1, are emerging as an important class of
cancer therapeutics, and a next generation of immunomodulatory therapies targeting alternative inhibitory (e.g. TIM-3,
LAG-3, B7-H4, B7-H3, VISTA, A2aR), as well as co-stimulatory (e.g. CD27, OX40, GITR, CD137), pathways are poised to join
them. Most of these immunomodulatory antibodies are of IgG isotypes that have low, or no, binding to the Fc gamma
receptors (FcγRs) that trigger cell-mediated cytotoxic effector functions such as antibody dependent cellular cytotoxicity
(ADCC) and phagocytosis (ADCP). These isotypes were selected to minimise the risk of depleting the T cells upon which
such antibodies depend for their mechanism of action. However, recent preclinical data highlight a potential role for
FcγR engagement in the activity of such antibodies. Here we review the biology of the FcγRs and IgG isotypes in both
humans and mice, detail the potential roles that FcγR interactions can play in the activity of monoclonal antibodies in
general, and of immunomodulatory antibodies in particular, and discuss how preclinical studies on these interactions
might be best interpreted and translated to a human setting.
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Antibodies of the IgG sub-class are bi-functional molecules,
possessing a F(ab) domain, variable in sequence and respon-
sible for the binding of antigen, and an Fc domain, constant
in sequence and responsible for mediating a range of anti-
body effector functions [1]. These functions are primarily
triggered through interaction with the complement compo-
nent C1q or with a family of FcγRs expressed, primarily, on
the surface of leukocytes. Each IgG isotype has a different
binding profile to the various FcγRs, and each FcγR has a
different cellular expression pattern. These differences en-
able the breadth, flexibility and control of function required
to mount an effective and regulated humoral response.
Effector functions mediated by the FcγRs, such as ADCC
and ADCP, are believed to play an important role in the ac-
tivity of several therapeutic antibodies; including a number
used in Oncology, for example rituximab and trastuzumab.
Antibodies targeting T-cell inhibitory pathways, such as
CTLA-4 and PD-1/PD-L1, are emerging as an important
class of cancer therapeutics, and a next generation of immu-
nomodulatory therapies targeting alternative inhibitory (e.g.* Correspondence: stewartr@medimmune.com
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unless otherwise stated.TIM-3, LAG-3, B7-H4, B7-H3, VISTA, A2aR), as well as
co-stimulatory (e.g. CD27, OX40, GITR, CD137), pathways
are poised to join them. In contrast to agents such as rituxi-
mab, most of these immunomodulatory antibodies are of
IgG isotypes that have low, or no, binding to the Fc gamma
receptors (FcγRs), and effects such as ADCC have not been
considered to be critical to their activity. Recent studies in
mice have, however, highlighted a potential role for FcγR
binding, and FcγR mediated effector functions in the activity
of antibodies targeting a number of these pathways.
Below we review the findings of these recent studies and
discuss how they may change our understanding of the role
FcγR interactions play in the activity of immunomodulatory
antibodies in mice. We begin, however, by reviewing the
biology of the FcγRs and IgG isotypes in mice and humans,
highlighting the key similarities and differences, which need
to be appreciated when thinking about how to translate
these findings to a human setting, in order to select the op-
timal isotype for any potential therapeutic.Review
The Fc gamma receptor family
Humans and mice possess two classes of FcγRs, the acti-
vating and inhibitory receptors. In both species FcγRI isl Ltd. This is an Open Access article distributed under the terms of the Creative
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expressed on monocytic DCs and on monocytes/macro-
phages broadly in humans but in select locations in
mouse (Table 1) [2,3]. FcγRI is the only FcγR with a
functionally meaningful binding affinity for monomeric
IgG, the remaining FcγRs all exhibit such low affinity for
the Fc region of IgG that functional engagement is only
expected to occur upon binding of antibody complexed
through antigen engagement (Table 2). Both species pos-
sess a single inhibitory FcγR, FcγRIIb, which is expressed
on B cells, DCs and basophils in both species, and found
additionally on monocytes, macrophages and all granulo-
cyte populations in mice (Table 1). The remaining FcγRs
are all activating, but more divergent between species.
In mice there are only 2 additional activating receptors
FcγRIII, which is expressed broadly on NK cells, mono-
cytes, macrophages, granulocytes and DCs, and FcγRIV,
which is found only on monocytes, macrophages and neu-
trophils. In humans there are four additional activating
FcγRs, the best characterised being FcγRIIa and FcγRIIIa.
FcγRIIa is expressed on granulocytes, monocytes and
monocyte-derived cells such as macrophages and DCs.
FcγRIIIa is expressed primarily on NK cells, but is also
found on monocytes and macrophages under some cir-
cumstances (Table 1). Each of these receptors exists as
two allotypic variants with differing binding affinity for
IgG (Table 2). For FcγRIIIa the more common F158 allo-
type has a lower affinity than the V158 allotype. For
FcγRIIa the more common H131 allotype has a higher
affinity than the R131 allotype [4]. The other two acti-
vating receptors are far less well characterised. FcγRIIc
is expressed in only 20% of people and is closely related to,
but expressed more restrictedly than, FcγRIIa. FcγRIIIb is
a GPI linked receptor expressed mainly on the sur-
face of neutrophils.
Mice and humans also have a divergent family of IgG
isotypes. In humans there are 4 isotypes, IgG1-4, each of
which has differing binding affinities to the various
FcγRs. Human (h)IgG3 demonstrates relatively high af-
finity binding to most FcγRs, but is not used routinely
as a therapeutic format (due to its long hinge region
and polymorphic nature which represent a stability andTable 1 Expression pattern of the major FcγRs in human and
Cell type FcγRI FcγRIIb
h m h m
B cells + +
DCs + + + +
NK cells
Monocytes/Macrophages + ~ ~ +
Neutrophils (+) ~ +
Italics indicates an inhibitory receptor. Normal text indicates an activating receptor.
expression, (+) indicates inducible expression and ~ indicates expression on only aimmunogenicity risk respectively) and will not be con-
sidered further in this review. Of the remaining isotypes
hIgG1 demonstrates the highest affinity for FcγRs, with a
nM or low μM binding affinity to all receptors (estimated
by surface plasmon resonance [SPR]), and is considered a
potent inducer of all cell mediated effector functions, such
as ADCC and ADCP. hIgG4 demonstrates a nM affinity
for FcγRI but μM affinities for all other receptors and is
considered a poor inducer of such effector functions.
hIgG2 has no measurable affinity for FcγRI, a high nM
affinity for the H131 form FcγRIIa and μM affinities for
all other FcγRs (Table 2).
These absolute affinities are a useful guide as to the
binding of the hIgG isotypes to hFcγRs relative to each
other. However, as noted above, the functional inter-
action between IgG and most FcγRs is not monomeric
in nature, as is modelled by SPR. In a study [5] examin-
ing the more functionally relevant binding of complexed
IgG to FcγRs on cells, the relative ranking of the isotypes
with respect to FcγR binding was retained, however no
binding of IgG2 to cells expressing the inhibitory FcγRIIb
or the F158 form of the activating FcγRIIIa could be de-
tected using this methodology, despite the interaction be-
tween IgG2 and these proteins demonstrated by SPR.
Mice also have four IgG isotypes but they are not
equivalent to those of human in either nomenclature or
properties. Mouse (m)IgG1, in contrast to hIgG1, is con-
sidered a low effector function isotype, since while it
binds inhibitory FcγRIIb and activating FcγRIII with nM
affinity, it has no measurable binding to activating FcγRIV.
In mice it is the two IgG2 isotypes, mIgG2a and mIgG2b,
that have the highest binding affinities to FcγRs, particu-
larly to FcγRIV (Table 2). In mice there is no IgG4 isotype,
and mIgG3 has no measurable FcγR interactions [6].
These differences in FcγR and antibody isotype inter-
actions and expression, summarised in Tables 1 and 2,
mean that there are no direct homologs between human
and mouse with respect to FcγR and antibody isotype
biology. However, it is possible to draw some parallels
between the species, for example mIgG2a and hIgG1 are
often considered equivalent functionally due to their
broad and high FcγR binding, while the generally lowermouse
hFcγRIIa mFcγRIII hFcγRIIIa mFcγRIV
+ +
+ +
+ + + +
+ + +
Human receptors are denoted by h and mouse receptors by m. + indicates
sub-set or on cells at specific physiological locations [2,3].
Table 2 Relative affinity of binding between the major
FcγRs and IgG Isotypes in human and mouse
Human Mouse
FcγR IgG1 IgG2 IgG4 FcγR IgG1 IgG2a IgG2b
I ++++ - ++++ I - ++++ ++++
IIa H131 +++ ++ ++ III ++ ++ ++
R131 +++ + ++
IIb ++ - ++ IIB +++ ++ +++
IIIa V158 +++ + ++ IV - +++ ++
F158 ++ - ++
Italics indicates an inhibitory receptor. Normal text indicates an activating
receptor. Rankings are based on KA x10
5M−1 for each interaction reported in
published studies [1,5,6]. ++++ indicates a KA greater than 100 x 10
5 M−1, +++
indicates a KA between 20 and 99 x 10
5 M−1, ++ indicates a KA between 1 and
19 × 105 M−1, + indicates a KA between 0.5 and 0.9 × 10
5 M−1, − indicates a KA
that was undetectable or less than 0.5 × 105 M−1.
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make them close functional analogs. Additionally the ac-
tivating mFcγRIII and hFcγRIIa are often considered
analogous based on affinities and expression pattern, as
are activating mFcγRIV and hFcγRIIIa. These parallels
are frequently imperfect though, for example: hFcγRIIIa
is expressed at high levels on NK cells, while mFcγRIV
is not; hFcγRIIa is not expressed on NK cells while
mFcγRIII is; mIgG1 is a more functionally restricted iso-
type than hIgG4, based on their relative affinities for ac-
tivating FcγRI, mFcγRIV and hFcγRIIa. These differences
need to be kept in mind, and pose challenges, when try-
ing to translate findings in mouse preclinical models to
humans.
The potential roles of FcγRs in the activity of therapeutic
antibodies
The FcγR mediated functions most commonly associated
with therapeutic antibodies are those that mediate target
cell elimination; ADCC, or the related ADCP. These
functions are triggered when antibody binding to antigen
on the surface of a target cell generates sufficient avidity
to trigger signalling through FcγRs on effector cells such
as NK cells and macrophages, which then eliminate tar-
get cells through direct killing or phagocytosis (Figure 1,
left). Preclinical models show that these forms of FcγR-
mediated cytotoxicity are a significant component of the
mechanism of action for tumor targeted antibodies such
as the anti-CD20 antibody rituximab and the anti-HER2
antibody trastuzumab [7]. The clinical evidence for the
role of such interactions, however, is more mixed. A
number of relatively small studies have shown improved
outcomes in patients that are homozygous for the higher
affinity allotypic forms of human FcγRIIIa and FcγRIIa
[8,9], supporting a role for FcγR-mediated cytotoxicity
in this setting, but several larger, randomized studies
have generally failed to show the same associations [4].Nevertheless a significant effort has been made to engineer
antibodies with improved affinity for the activating FcγRs
[10-12], with the aim of enhancing these cytotoxic func-
tions and improving therapeutic efficacy, and the outcome
of clinical trials with such agents may provide further clar-
ity as to the true contribution of FcγR mediated cytotox-
icity in activity.
An alternative role for FcγRs is in the activity of anti-
bodies that function by agonising cell surface receptors,
for example those of the tumor necrosis factor receptor
(TNFR) super family. In this context binding of IgG Fc
to FcγRs results in higher order clustering of antibody.
This in turn results in higher order clustering of the target
receptor when bound by the F(ab) domain, which triggers
downstream signalling (Figure 1, right). This clustering
effect has been shown to be critical to the activity of
antibodies specific for the TNFR family members CD40
[13,14] death receptor 5 (DR5) [15,16] and CD95 (Fas) [17]
in preclinical mouse models, and has been suggested to
play a similar role in the activity of other TNFR agonists
such as anti-OX40 and anti-CD27 [18].
The canonical role of FcγRs in immunomodulatory
antibodies
Immunomodulatory antibodies mediate their beneficial
effects by promoting anti-tumor immunity. There are a
number of potential ways to achieve this, but one area
showing particular promise is the use of antibodies that
antagonise inhibitory receptors on the surface of T cells.
One such antibody, the anti-CTLA-4 ipilimumab, was
approved based on its ability to improve survival in
metastatic melanoma patients [19], while a number of
antibodies targeting PD-1 are showing highly encour-
aging results in phase 1 clinical trials [20,21]. An alterna-
tive approach, which is earlier in clinical development
but also showing promise, is the use of antibodies that
agonise co-stimulatory receptors. The agonistic anti-CD40
antibody, CP870,893, has demonstrated early signs of activ-
ity in pancreatic cancer [22], and tumor shrinkage was also
observed in some patients treated with agonistic antibodies
directed against OX40 [23] and CD137 [24].
As mentioned above FcγR engagement has been
shown to be critical for the activity of antibodies that ag-
onise the TNFR CD40 in mice. The anti-tumor activity of
anti-mouse CD40 in these studies is lost upon introduc-
tion of the D265A mutation into its Fc domain [13],
which results in an antibody with no measurable FcγR
binding [6]. It has also been shown that the in vitro activ-
ity of antibodies directed against other TNFRs in human
cells, such as OX40, GITR, CD137 and CD27, requires,
or is greatly enhanced by FcγR engagement or immobil-
isation [25,26]. While the evidence suggests that a re-
quirement for cross linking is a common property of
antibodies targeting TNFRs receptors, there are some
Figure 1 The two primary forms of interaction between therapeutic IgGs and FcγRs. On the left: when IgG is bound to high levels of
antigen on target cells, such as tumor cells, the resulting clustered Fc domains engage with FcγRs on immune effector cells such as NK cells and
macrophages. This drives signals through those FcγRs triggering the initiation of cell-mediated effector functions such as ADCC and ADCP. On
the right: when IgG is bound by its Fc domain to FcγRs it can act to cluster low levels of target receptors, such as members of the TNFR family.
This clustering acts to trigger signals though the TNFR into target cells, such as T cells.
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mAb has demonstrable agonistic properties in the soluble
phase [27], the anti-CD40 antibody CP870,893 has been
shown to function in vitro in solution and as a F(ab)’2
fragment that lacks any Fc domain [28] and the anti-
OX40 antibody 9B12, which is a mouse IgG1 with very
low affinity interactions with FcγRs, has shown early
signs of clinical activity and demonstrated the ability to
activate T cells in patients [23].
Two studies that further explored the role of FcγR en-
gagement for the activity of anti-mouse CD40 demon-
strated that it is the inhibitory mouse FcγRIIb that plays
an essential role [13,14]. One of these studies [14] went
on to demonstrate that other mouse FcγRs are capable
of cross linking anti-CD40 to drive activity in vitro, and
proposed that the dominant role of FcγRIIb in vivo was
due primarily to its bioavailability at the site of action
for anti-CD40, namely the secondary lymphoid organs.
Both studies also went on to show that the activity of
anti-mouse CD40 was lost upon class switching from a
mouse (m)IgG1 to a mIgG2a. Two alternative, and non-
mutually exclusive, hypotheses exist to explain this obser-
vation. The first is that the reduced affinity of mIgG2a for
FcγRIIb results in reduced cross linking at the relevant site
of action and so limits activity [14]. The second is that the
loss of activity occurs due to increased depletion of CD40
positive cells, which are predominantly antigen presentingcells (APCs) critical to mounting an adaptive immune
response [13]. In the case of the second hypothesis, the
balance of FcγR engagement would become critical to
the activity of anti-CD40. Too little engagement, as
seen with alglycosyl antibodies, and no agonistic signal-
ling is triggered so no anti-tumor activity is observed.
Too much FcγR engagement on effector cells and deple-
tion of critical immune cells begins to occur and anti-
tumor activity is once again lost. Such a trade off in FcγR
affinity could also apply to other immunomodulatory anti-
bodies that target TNFRs (CD27, OX40, GITR, CD137),
which are also expressed on critical immune cells. In
addition it has been shown that for CD137 antibody medi-
ated internalisation of receptor can play a role in driving
signalling [29], and it is unclear how changes in Fc isotype
might affect this property.
For those antibodies that target inhibitory receptors
like PD-1 and CTLA-4 there has been little reason to
believe, based on their antagonistic mechanism of action,
that FcγR engagement plays an important role in their
activity, and no significant evidence to contradict this
belief exists in the clinical setting. Since all of the anti-
gens targeted by these antibodies are expressed either on
T cells or on APCs, the preference has been to select iso-
types that will avoid the risk of depleting these cells
through Fc mediated mechanisms; an outcome that would
likely negate any beneficial immune activation. As a result,
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currently in clinical development is that they are low or
null effector function isotypes (Table 3). Main exceptions
include ipilimumab (anti-CTLA-4), MSB0010718C (anti-
PD-L1) and antibodies like MGA271 (anti-B7-H3), CDX-
1127 (anti-CD27) and alemtuzumab (anti-CD52) which
employ ADCC of tumor cells as a part of their mechanism
of action.
However, several recent preclinical studies are calling
into question the view that all TNFR agonist antibodies
will behave as anti-CD40 does, or that all antibodies tar-
geting inhibitory receptors will be maximally effective as
a low or null effector function isotype.
The evolving role of FcγRs in immunomodulatory
antibodies
Three recently published studies [31-33] have examined
the role of mouse FcγRs in the activity of anti-mouse
CTLA-4 antibodies. In these studies anti-mouse CTLA-4
antibodies were studied in a range of syngeneic tumor
models where they have previously shown activity, includ-
ing MC38 (colon), CT26 (colon) and B16 (melanoma). The
approach taken to examine the role of FcγRs varied be-
tween studies and either involved the use of FcγR knock
out mice [31,33] or reformatting of the anti-mouse CTLA-
4 to a variety of different antibody isotypes [32]. Irrelevant
of the approach taken the result was the same; the activity










MSB0010718C PD-L1 Merck KGaA
BMS-663513 CD137 BMS
PF-05082566 CD137 Pfizer




Lirilumab; IPH2102 KIR BMS/Innate Pharma
MGA271 B7-H3 Macrogenics/Servier
Alemtuzumab CD52 Genzyme/Bayer
IgG1 TM = IgG1 triple mutant, which contains 3 point mutations in the Fc domain tengagement of the activating FcγRs in mouse tumor
models. Further examination of the mechanism for this
dependence revealed that in the lymph nodes anti-mouse
CTLA-4 acted to increase the number of CD4 T cells, in-
cluding regulatory T cells (T-regs), but that within the
tumor it acted to selectively deplete only T-regs [33]. In
one of the three studies, a comparison of several different
anti-mouse CTLA-4 antibodies showed that the extent of
T-reg depletion observed correlated with activity [33].
The depletion of T-regs was mediated predominantly
by mouse FcγRIV, but was independent of NK cells, and
considered likely to rely on the activity of intratumoral
CD11b +macrophages [33]. In all three studies the level of
CTLA-4 expression was shown to be increased on intratu-
moral T cells relative to those in lymph nodes, and was
higher on T-regs than on other T cell sub-sets.
In their study Bulliard et al. [31] also examined the
role of mouse FcγRs in the activity of the anti-mouse
GITR antibody DTA-1. In contrast to the observations
made for anti-mouse CD40, DTA-1 activity was minim-
ally affected by the absence of inhibitory FcγRIIb, but
was dependent on the presence of the activating mouse
FcγRs [31]. In further contrast to anti-CD40, a mouse
(m)IgG2a version of DTA-1 was equal in activity to the
parental rat IgG2b version; although no mIgG1 was
tested. Analogous to the mechanism observed for anti-
mouse CTLA-4, it was shown that while mIgG2a or rat
IgG2b forms of DTA-1 treatment resulted in expansion ofnical development and their respective isotypes



















hat reduce the binding affinity of the mAb to FcγRs [30].
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plete T cells within the tumor. Also similar to anti-mouse
CTLA-4, this depletion preferentially occurred in the T-reg
compartment and, although some reduction in both con-
ventional CD4+ and CD8+ T cells was also observed, re-
sulted in an increase in the CD8:T-reg ratio within the
tumor. In a more recent study published earlier this year
Builliard et al. [34] demonstrated a comparable mechan-
ism, and dependence on activating mouse FcγRs for an
anti-mouse OX40 antibody. It is however worth noting
that alternative studies have proposed, and evidenced,
a mechanism of regulatory T cell re-programming for
DTA-1 [35] and for anti-human OX40 mAbs [36], sug-
gesting that a loss of FOXP3 expressing T cells following
treatment with agents targeting either pathway may not
necessarily equate to depletion.
These preclinical studies have brought into question
two generally held beliefs regarding the role of FcγRs in
the activity of immunomodulatory antibodies. The first
is the idea that inhibitory FcγRIIb is the critical receptor
for the activity of all TNFR agonist antibodies. The data
generated for the anti-mouse GITR antibody DTA-1
clearly demonstrate FcγRIIb independent activity, and
our own unpublished data demonstrates similar inde-
pendence for other TNFR targeting antibodies. These
data suggest, as previously proposed by White et al., that
the specific mouse FcγRs involved in cross linking of
TNFR agonists may vary depending on the pathway be-
ing targeted and on the bioavailability of each of the
FcγRs at the primary site of action. The second is the
idea that effector function enabled antibodies represent
a risk to activity due to depletion of key immune cell
sub-sets. Importantly the data highlight the fact that per-
ipheral and intratumoral antibody mediated effector
function are far from equivalent. This difference appears
to hinge on two critical differences; the level of target
antigen expression and the presence of appropriate ef-
fector cells (Figure 2).
The extent of effector function triggered by antibody
binding has been shown in a number of studies to be
strongly influenced by the level of target antigen expres-
sion [37,38], with antibodies directed against both hu-
man CCR4 and CD20 failing to elicit in vitro ADCC
against human tumor cell lines expressing anything less
than 104 antigen molecules per cell and reaching optimal
activity only in the presence of 105-106 antigen mole-
cules [37]. Many of the targets for immunomodulatory
antibodies are expressed at low to undetectable levels on
resting, peripheral immune cells, but are up-regulated
significantly in the presence of pro-inflammatory stimuli,
such as those present in the tumor microenvironment.
As such, and in the light of recent studies, it is clear that
in mouse models it is significantly easier to elicit effector
function against intratumoral immune cells. Additionallyeffector function is entirely dependent upon the pres-
ence of FcγR-bearing effector cells at an appropriate
density. The studies by both Simpson et al. and Bulliard
et al. highlight what many of us will have observed in
our own work, that there are very few effector cells, such
as NK cells, neutrophils and macrophages, present in
lymph nodes, which are dominated by T, B and dendritic
cells. What both studies additionally show is that mouse
tumors are extremely rich in FcγR-expressing effector
cells. Simpson et al. evidence greater than 20% NK cells
and greater than 40% CD11b + cells, which are predom-
inantly macrophages, in B16 tumors and Bulliard et al.
highlight very similar levels of the same cells in CT26
tumors. The coincident presence of high levels of target
antigen and a high density of effector cells creates a per-
fect storm for Fc mediated effector function within the
tumor, while the lower target expression and relative
paucity of effector cells in the periphery makes the same
effector function harder to achieve in the lymph node. It
is however worth noting that peripheral depletion of im-
mune cells is possible, as demonstrated by the data on
anti-CD40 [13] and the well documented effects of anti-
CD20 [39], suggesting that the nature or expression level
of the target are likely critical.
Translating preclinical data to man
As outlined at the start of this review, the significant dif-
ferences between human and mouse FcγR and IgG iso-
type biology make translation of findings between species
extremely challenging, and several factors need to be con-
sidered and better studied in the human setting before
these findings can be confidently applied to the activity of
therapeutic antibodies in man.
Taking anti-CTLA-4 as an example, the first signifi-
cant translational challenge is the key role for mouse
FcγRIV in the T-reg depleting activity demonstrated for
anti-mouse CTLA-4. FcγRIV does not exist in humans,
and its closest analog, human (h)FcγRIIIa, is expressed
predominantly on NK cells, which played no role in the
mainly macrophage mediated T-reg depletion observed
with anti-mouse CTLA-4 [33]. In humans macrophages
can express hFcγRIIIa following certain stimuli, such as
IL-10, but primarily express hFcγRIIa/b and hFcγRI, and
it is feasible that in human tumors these receptors would
play the same role as mouse FcγRIV does in mouse tu-
mors. Further study of the intratumoral effector cell and
FcγR constituent within human tumors would be ex-
tremely helpful in understanding which human FcγR
might play the role of mouse FcγRIV in humans.
The second challenge for translation lies in the differ-
ences between IgG isotypes across species. In mice only
mouse (m)IgG2a and mIgG2b demonstrate any measur-
able binding to mouse FcγRIV; mIgG1 can therefore
show none of the T-reg depleting activity observed for
Figure 2 Critical differences between effector function in the periphery relative to the tumor. On the left: in lymph nodes, relatively low
levels of cell activation and pro-inflammatory cytokines result in low levels of expression for most targets of immunomodulatory antibodies, which
are generally low on resting immune cells. This low level of target expression, together with a paucity of effector cells in lymph nodes means
depletion of cells through cell mediated effector functions do not readily occur. On the right: high levels of pro-inflammatory cytokines within
the tumor microenvironment trigger up-regulation of many targets. This increased target expression together with a high density of effector cells,
such as macrophages, enables depletion of cells through cell-mediated effector functions. The level of target expression, and the sensitivity to
depletion varies across cell types and favours depletion of T-regs for targets such as CTLA-4 and GITR.
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IgG1 has a significantly higher binding affinity to all human
FcγRs, hIgG2 and hIgG4 are both capable of interact-
ing with human FcγRIIa and IIIa, and while human
FcγRI cannot bind hIgG2, its high affinity for monomeric
IgG suggests that it would be heavily occupied by serum
IgG and less available to partake in effector function [40].
Critically, while hIgG2 and hIgG4 are both very poor
mediators of NK cell driven ADCC, they are both cap-
able of mediating ADCC via PBMCs, monocytes and
neutrophils [41,42]. It is especially conceivable that in a
tumor microenvironment, with its increased target anti-
gen levels and high density of effector cells, that a hIgG2
or hIgG4 could begin to mediate some degree of ADCC
or ADCP. If one were to assume that a mouse IgG2a
were equivalent to human IgG1 and mouse IgG1 equiva-
lent to human IgG2 then the data of Selby et al. would
predict significant differences in the two anti-CTLA-4
antibodies that have been tested clinically one of which,
tremelimumb, is a human IgG2 and the other of which,
ipilimumab, is a human IgG1 currently registered for the
treatment of metastatic melanoma. The complex differ-
ences in FcγR and IgG isotype biology that exist between
species, outlined above, suggest however that such as-
sumptions about the comparability of mouse and human
IgG isotypes may be too reductionist. In relation to
this, while no definitive comparison of the two agents
has been conducted, the toxicity profiles of ipilimumab
and tremelimumab are comparable [19,43] and a recent
commentary in the Journal of Clinical Oncology [44]
highlighted the very limited differences observed in the3 year survival rate seen in melanoma patients treated
with the two agents.
The third translational challenge relates to the key
driver for differential depletion of T-regs relative to
other cell types in all three of the published studies, that
is target expression level. It is clear from the published
studies that the levels of GITR and CTLA-4 on mouse
T-regs is higher than that observed on mouse effector
T cells, in particular CD8s. However there are no studies
available comparing how the level of target expression
varies between mice and humans, few that compare the
differential expression of target on human T-regs relative
to effectors, and none that examine how this expression
changes quantitatively in the tumor versus the periphery.
These are all significant variables that must be studied in




Immunomodulatory antibodies are showing positive re-
sults in early clinical trials in cancer. These antibodies
generally fall into two classes. Those that antagonise in-
hibitory receptors, such as CTLA-4 and PD-1, and those
that agonise stimulatory receptors, such as CD27, OX40,
GITR and CD137.
Many groups, including our own, have been working
to study the requirement for FcγRs in the activity of TNFR
agonist antibodies, but the recent study of Bulliard et al.
[31] has further highlighted the potential complexity of this
requirement by providing evidence that inhibitory mouse
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http://www.immunotherapyofcancer.org/content/2/1/29FcγRIIb is not required for the activity of all TNFR agonist
antibodies in mice, as has been previously suggested. Fur-
ther work is required to pull apart the target specific nature
of FcγR requirements for mAb activity and the relative
contributions of pathway agonism versus targeted deple-
tion of cells. In the case of TNFR agonists pulling these
apart is made very difficult by the inability to divorce FcγR
cross linking, and therefore agonism, from effector func-
tion for the majority of such antibodies.
The study by Bulliard et al. [31], together with that of
Selby et al. and Simpson et al. [32,33], also highlighted
the previously underappreciated difference between FcγR-
mediated effector function in the periphery as compared to
the tumor microenvironment in mice and highlighted the
unexpected potential role of FcγRs in the activity of immu-
nomodulatory antibodies that target the inhibitory receptor
CTLA-4 in mice. Based on these studies it will be interest-
ing to see how FcγR interactions may impact antibodies
targeting PD-1 or PD-L1, which have very different expres-
sion patterns to CTLA-4, despite their shared inhibitory
function.
The most important future studies however will be
those that address the translatability of these findings in
mouse preclinical models to man. While their exact
value remains unconfirmed [4], studies exploring the im-
pact of human FcγR polymorphisms on clinical activity
may shed further light on how critical individual recep-
tors are to the mechanism of specific immunomodula-
tory antibodies. To this end a study presented at ASCO
in 2013 [45] reported no difference in response to the
anti-CTLA-4 ipilimumab in patients with the high ver-
sus low affinity allotypic forms of human (h)FcγRIIIa or
hFcγRIIa. The triggering of effector function is however
a complex process; the result of an ill-defined interplay
between target expression, IgG affinity for FcγR, FcγR
expression patterns on different leukocytes and density
of those leukocytes that mediate effector function, such
as NK cells and macrophages. These are all variables
which could diverge significantly between species. Ultim-
ately further studies in human in vitro systems and in pri-
mary tissue samples, preferably from patients treated with
immunotherapy agents, will be the most effective way to
determine the comparability of these variables between hu-
man and mouse. It is these studies that will serve to move
the translation of this key aspect of biology forward and
aid in the design of more effective therapeutics.
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